1. Introduction {#sec1-molecules-25-00938}
===============

MET receptor is a multifunctional receptor tyrosine kinase that plays a pivotal role in human development and tumorigenesis. Upon binding of its ligand HGF (Hepatocyte Growth Factor), MET triggers several intracellular signaling cascades, including MAPK and PI3K pathways, leading to various cellular responses, such as survival, proliferation, and migration, among others. MET activation can be driven in cancer by several mechanisms: HGF or MET overexpression, and also mutations \[[@B1-molecules-25-00938]\].

Aberrant activation of MET signaling does not only affect cancer development and progression, but it also contributes to resistance against other cancer drugs \[[@B2-molecules-25-00938],[@B3-molecules-25-00938],[@B4-molecules-25-00938],[@B5-molecules-25-00938],[@B6-molecules-25-00938],[@B7-molecules-25-00938],[@B8-molecules-25-00938],[@B9-molecules-25-00938],[@B10-molecules-25-00938],[@B11-molecules-25-00938]\]. Consequently, MET represents a pharmaceutically relevant target in anticancer drug design and has been the focus of several anticancer strategies \[[@B12-molecules-25-00938],[@B13-molecules-25-00938],[@B14-molecules-25-00938],[@B15-molecules-25-00938],[@B16-molecules-25-00938],[@B17-molecules-25-00938],[@B18-molecules-25-00938]\]. Pioneer MET inhibitors such as SU11274, PHA665752, or AM7 were helpful for demonstrating the efficacy of MET inhibition to impair tumor growth in preclinical models. Then, further developments in the field led to the approval by the FDA of crizotinib and cabozantinib in the 2010s for treating non-small cell lung cancers and medullary thyroid cancers, respectively.

Even though promising results have been reported, the therapeutic activity of these drugs is still relative and efforts are required to identify new MET inhibitors with physicochemical properties optimized for clinical efficiency \[[@B19-molecules-25-00938],[@B20-molecules-25-00938]\]. Moreover, new alterations in MET sequence have been recently identified, such as MET exon 14 skipping in lung cancers and the emergence of MET mutations in the kinase domain following treatment with MET inhibitors \[[@B21-molecules-25-00938]\]. Novel inhibitor structures may possibly target these mutations with increased efficiency.

Designing new putative hits against MET therefore remains a valuable challenge to be tackled. In the present work, we carried out a virtual screening campaign in order to identify innovative compounds able to become new hits for further lead development. As MET plasticity upon ligand binding had been previously highlighted \[[@B22-molecules-25-00938],[@B23-molecules-25-00938]\], we took into account this aspect for the molecular docking simulations. Indeed, MET can accommodate several distinct ligand binding modes and associated receptor conformations, a feature that is particular to the kinase family \[[@B24-molecules-25-00938]\]. We reasoned that it should be taken into account for designing drugs with improved efficiency and selectivity profiles \[[@B25-molecules-25-00938],[@B26-molecules-25-00938]\]. To be efficient, the molecular docking engines embedded within the virtual screening approaches must be adapted to handle such flexibility \[[@B27-molecules-25-00938],[@B28-molecules-25-00938]\]. In the present work, we used the ensemble-docking strategy---previously recognized for its efficiency in drug design \[[@B29-molecules-25-00938]\]---and show the benefit of an investigation using a large ensemble-docking on MET.

In previous medicinal chemistry works, we already identified novel MET inhibitors \[[@B30-molecules-25-00938],[@B31-molecules-25-00938]\] and characterized the different MET ligand binding modes as shown by the stream of released X-ray data \[[@B32-molecules-25-00938]\]. Here, we provide the results of a large-scale ensemble-docking investigation on MET, in which MET conformations are extended from available X-ray data to molecular dynamics and normal mode analysis. A limited number of candidate compounds were selected from the ensemble-docking results and one of them was subsequently validated experimentally as a possible new MET inhibitor, providing a valuable seed for further investigations.

2. Materials and Methods {#sec2-molecules-25-00938}
========================

2.1. Screened Chemical Libraries {#sec2dot1-molecules-25-00938}
--------------------------------

The choice of an appropriated set of compounds to explore the virtual screening space is critical for assuming a good rate of success \[[@B33-molecules-25-00938]\]. Today, millions of compounds can be selected for high-throughput screening, and a suitable selection strategy must be designed. In our case and according to previous success stories \[[@B34-molecules-25-00938],[@B35-molecules-25-00938],[@B36-molecules-25-00938]\], we chose to use a set of libraries selected in order:To use the highest possible chemical diversity, in order to cover a large spectrum of chemical structures \[[@B37-molecules-25-00938],[@B38-molecules-25-00938],[@B39-molecules-25-00938],[@B40-molecules-25-00938]\];To include kinase-targeted compounds, as such a choice is already proven to be successful \[[@B41-molecules-25-00938],[@B42-molecules-25-00938]\];To explore natural products, which are a promising source of anticancer drugs \[[@B43-molecules-25-00938],[@B44-molecules-25-00938],[@B45-molecules-25-00938]\];To take into account the repositioning of approved compounds, as drug repurposing presents an increasing interest in cancer research, by removing many costs associated with several steps of drug development \[[@B46-molecules-25-00938],[@B47-molecules-25-00938],[@B48-molecules-25-00938],[@B49-molecules-25-00938]\]. Several proofs of concept are now available and a typical case of viral-to-cancer drug repositioning is gemcitabine with US patent No 4,808,614, aimed at treating viral infections, and the later-issued US No 5,464,826, which claims of its use to treat cancer. Therefore, we also considered chemical libraries dedicated to antiviral compounds.

According to the criteria listed above concerning the choice of the chemical libraries, we firstly downloaded around 200,000 compounds from the chemical providers listed in [Table 1](#molecules-25-00938-t001){ref-type="table"}. After eliminating redundancies in compounds and in scaffolds to assume a large chemical diversity and in respect of general druglike definitions \[[@B50-molecules-25-00938]\], we finally retained about 80,000 compounds for our screening campaign.

2.2. Selected MET Conformational Ensemble {#sec2dot2-molecules-25-00938}
-----------------------------------------

In ensemble-based docking calculations, a well-suited choice of the protein target conformational sample is required to reproduce the protein plasticity and the possible induced-fit phenomena \[[@B51-molecules-25-00938],[@B52-molecules-25-00938]\].

Concerning MET conformational flexibility, our previous exploration by molecular dynamics and normal mode simulations \[[@B22-molecules-25-00938]\] was limited to the 26 PDB structures available at that time ([Table 2](#molecules-25-00938-t002){ref-type="table"}). We have now extended this analysis by considering all the X-ray structures available for the wild-type MET in the PDB \[[@B53-molecules-25-00938]\] deposited after 2012. From the additional structures found, only 19 were considered in this work ([Table 3](#molecules-25-00938-t003){ref-type="table"}) as we discarded those where three regions were missing in the X-ray structure and those where the number of missing residues in a single region was larger than 20. This selection aimed to improve our protein ensemble sample by covering most of the kinase structural characteristics, such as the position of the c-helix (in or out) or of the aspartate-phenylalanine-glycine (DFG) motif (in or out) as defined in Kinametrix \[[@B54-molecules-25-00938]\], thus covering most of the inhibitor type binding modes. 3D structures considered in this ensemble of 45 conformers looked representative of the diversity of MET structures, as shown from the dendrogram, the heat maps, and correspondence maps in [Figure 1](#molecules-25-00938-f001){ref-type="fig"}. These results obtained thanks to the Dali server \[[@B55-molecules-25-00938]\] clearly illustrate how MET 3D structures used here are organized into several families covering most of the protein conformational space presently known.

To be in accordance with the 26 conformers coming from our previous work \[[@B22-molecules-25-00938]\], the 19 added crystal structures were prepared and cleaned following the same protocol: missing residues, side chains, and hydrogens were added when necessary; unnecessary water molecules, ions, and additives were removed; basic and acidic side chains were ionized according to a pH set to 7. To consider possible binding sites fluctuations, short molecular dynamics (MD) simulations were undertaken for each of these 19 structures. For that purpose, these structures were placed in a solvent box of 80 Å and counter ions were added for electrostatic neutrality. NAMD \[[@B57-molecules-25-00938]\] molecular dynamics program was used with the same CHARMM36 force field and same protocol as previously described \[[@B22-molecules-25-00938]\]. After minimization and equilibrium steps (64,000 conjugate gradients and 1 ns MD, respectively), 10 ns of MD were recorded, with a frame length of 1 ps. These 19 MD trajectories were analyzed, and the most stable representative conformer was retained for each of them and added in the ensemble-docking set.

2.3. Description of the Ensemble-Docking Protocol {#sec2dot3-molecules-25-00938}
-------------------------------------------------

The ensemble-docking facility proposed in the GOLD docking program was used \[[@B58-molecules-25-00938]\]. This GOLD feature evaluates different receptor conformations concurrently during the docking exploration. The protein ensemble used in this work thus contained 45 MET conformers (26 from our previous work and 19 added in this one). As these conformers must be superimposed before being used in GOLD ensemble-docking program, they were structurally aligned according to their conserved and most rigid secondary structure patterns, as previously described \[[@B22-molecules-25-00938]\] and summarized in [Table 4](#molecules-25-00938-t004){ref-type="table"}.

When docking an ensemble of conformations for a given protein, their binding sites must be defined using a method that is not conformer specific. In the present ensemble-GOLD version, as it was not possible to define the active site by a list of atoms or residues, the only way was to use the centroid of the binding cavity and a sphere radius around this point. Therefore, for each of the 45 aligned protein conformers used here, protein cavities and their center of mass were detected by the LIGSITE program \[[@B59-molecules-25-00938]\]. From these data, we obtained an average center point as the ensemble binding site definition for GOLD. [Figure 2](#molecules-25-00938-f002){ref-type="fig"} presents the position of this average center point within the 45 protein conformers. A radius of 20 Å was associated to this average point to define the binding cavity of each conformer in order to correctly encompass the receptor for all the conformations in the ensemble, including conformational variations around the center. We also verified that the resulting sphere was encompassing all groups of residues previously identified as potential interaction areas for MET ligands \[[@B32-molecules-25-00938]\].

For each docking run, we used 50 starting poses/molecule for the GOLD generic algorithm. Tested compounds were ranked by the standard goldscore scoring function.

2.4. Computer Grid Facilities {#sec2dot4-molecules-25-00938}
-----------------------------

Due to the massive calculations needed ( 80,000 molecules × 48 protein ensemble conformers × 50 poses/molecule), and considering the computing time to achieve only one run, we used the Grid5000 facility \[[@B60-molecules-25-00938]\] providing the required computer power in order to distribute the calculations using the PVM framework embedded in GOLD. A total of 1300 cpus (mostly Xeons) with 4 GB RAM/core and infiniband connections were used for each run. The docking performances run around 300-docked ligands/ensemble/hour. The calculations were spread on the clusters using the same strategy as previously described \[[@B61-molecules-25-00938]\].

2.5. Scattering Assays {#sec2dot5-molecules-25-00938}
----------------------

The experimental protocols for measuring the potency of MET inhibitors are detailed in previous publications \[[@B30-molecules-25-00938],[@B62-molecules-25-00938]\]. MDCK cells were preincubated with compounds overnight at 0.1--100 $\mathsf{\mu}$M concentrations at 37 °C in a humidified atmosphere of 5% CO${}_{2}$, followed by a 24 h stimulation with 20 ng/mL HGF (R&D Systems). Cells were further incubated at 37 °C in an atmosphere of 5% CO${}_{2}$ for 24--48 h, washed with phosphate buffered saline (PBS; Gibco BRL), and fixed with 4% PFA (paraformaldehyde, Sigma). The quantification of scattering response was performed by counting the number of cells with scattered morphology in 30 independent colonies. The IC${}_{50}$ corresponds to the concentration of compounds leading to a 50% inhibition of MET-triggered cell scattering.

3. Results {#sec3-molecules-25-00938}
==========

3.1. Preliminary Validation Concerning the GOLD Ensemble-Docking Protocol Used {#sec3dot1-molecules-25-00938}
------------------------------------------------------------------------------

The coordinates of the 45 aligned conformers and of the sphere representing their common binding sites constituted our ensemble-docking protein reference.

The first question here concerned the accuracy of this binding site definition compared to ones that are more classical. For that, we compared the docking results for some of the selected 45 MET conformers using three binding site definitions; namely, a residue list, an existing ligand, and the center point of the binding cavity, respectively. For each individual docking target, the three definitions provided almost the same rank and docking score for the associated PDB ligand ([Table 5](#molecules-25-00938-t005){ref-type="table"}). Moreover, the poses of this ligand found using the three binding site definitions were similar to the pose found in the crystal structures, as illustrated with the example of the AM7 ligand on [Figure 3](#molecules-25-00938-f003){ref-type="fig"}.

The second question was related to the ability of the ensemble-docking process to retrieve a given PDB ligand to its PDB structure among the 45 ones. To evaluate that point, an ensemble-docking calculation was carried out on the 45 protein target conformers using a short chemical library built from their own 45 associated ligands (the list is given in [Table 2](#molecules-25-00938-t002){ref-type="table"} and [Table 3](#molecules-25-00938-t003){ref-type="table"}). We checked whether we could associate the right PDB target for a given PDB ligand (with possibly similar rank, score and pose compared to the ones found for the individual target dockings) in the protein ensemble. This was achieved for almost 80% of the compounds ([Table S1](#app1-molecules-25-00938){ref-type="app"}). For example, the KSA ligand was able to preferentially retrieve its original 1R0P partner among the ensemble of the 45 PDB conformers of the protein target.

From these results, it appeared that the ensemble-docking procedure we used was a satisfactory method to tackle multiple conformers docking and to achieve a valuable virtual screening.

3.2. Selection of Candidate Hits from the Virtual Screening Campaign {#sec3dot2-molecules-25-00938}
--------------------------------------------------------------------

Once the screening campaign was achieved for the 80,000 compounds filtered from the chosen libraries, we kept the top-100 ranked compounds according to their GOLD scores (ranging from 100 to 114) for further analysis.

We started the docking analysis with the Life Chemicals compound F0725-0356 giving the best docking score of 114. A comparison between the X-ray complex 3EFK/MT4 structure and the MD_3EFK/F025-0356 one presented quite similar poses and protein/ligand interactions. Indeed, the most important residues known in MET interactions (namely, Met${}_{1160}$, Asp${}_{1222}$, Tyr${}_{1159}$) were found in both complexes.

We next analyzed the protein-ligand interactions for the other top-100 compounds in order to compare them to the ones found in the 45 original PDB structures ([Table 2](#molecules-25-00938-t002){ref-type="table"} and [Table 3](#molecules-25-00938-t003){ref-type="table"}). For that, we used the PLIP program \[[@B63-molecules-25-00938]\] by focusing on two important interaction types: hydrogen bonds and $\pi$-stacking. Protein residues Met${}_{1160}$ (45/45), Asp${}_{1222}$ (34/45), and Lys${}_{1110}$ (6/45) concentrated the vast majority of hydrogen bonds with ligands; while Tyr${}_{1230}$ (25/45) and Phe${}_{1223}$ (7/45) dealt with most of the $\pi$-stacking. In order to limit our biological tests on possible promising compounds, we eliminated from the top-100 list the molecules not presenting at least one hydrogen bond and one $\pi$-stacking from the ones described above in the PDB complexes.

After this filter, we retained only 41 compounds as satisfying these criteria. As most of these compounds came from the Life Chemical antiviral library and given the simplicity of comparing molecules from the same supplier, we decided to only test compounds from Life Chemicals. As some of these molecules were not available in stock from this provider, only the 25 compounds listed in [Table 6](#molecules-25-00938-t006){ref-type="table"} were finally kept to proceed further.

3.3. F0539-1482 and F0514-4011 Inhibit MET-Induced Cell Scattering {#sec3dot3-molecules-25-00938}
------------------------------------------------------------------

These 25 compounds were then experimentally tested for their ability to restrain MET-triggered biological activities. We previously efficiently screened compounds for their inhibitory properties towards MET-triggered biological responses by using cell scattering assays \[[@B31-molecules-25-00938],[@B64-molecules-25-00938]\]. In particular, MDCK epithelial cells acquire a "scattered phenotype" after stimulation with MET ligand HGF.

Among the 25 tested compounds, two compounds were found active, namely, F0539-1482 and F0514-4011. F0514-4011 was the most efficient and impaired this scattering response to HGF with an IC${}_{50}$ of 7.2 $\mathsf{\mu}$M ([Figure 4](#molecules-25-00938-f004){ref-type="fig"}). No toxic effects were observed at biologically active concentrations. This study thus demonstrates that our strategy actually allows the identification of compounds able to inhibit MET-driven biological activities.

3.4. Compared Docking of F0514-4011 Compound Versus Known Inhibitors {#sec3dot4-molecules-25-00938}
--------------------------------------------------------------------

In order to understand why the compound F0514-4011 ([Figure 5](#molecules-25-00938-f005){ref-type="fig"}) was the most potent compound among the 25 experimentally tested ones while not presenting the highest GOLD score, we compared its docking data with those of potent existing inhibitors. For that, we collected the structures of ligands found in the PDB related to MET kinase domain in complex with already marketed inhibitors with binding IC${}_{50}$ found in the nM range ([Table 7](#molecules-25-00938-t007){ref-type="table"}). All these compounds were submitted to the ensemble-docking GOLD protocol already used for our virtual screening campaign. From these calculations, it appeared that the best docking scores ranged from 111 for merestinib (L1X ID in PDB 4EEV) to 83 for AMG337 (5T1 ID in PDB 5EYD), so that the score of 103 obtained for our active F0514-4011 compound was in this range of active compounds. Considering now IC${}_{50}$, one possibility to explain the higher IC${}_{50}$ of 7.2 $\mathsf{\mu}$M obtained for F0514-4011 (compared to 0.4--14 $\mathsf{\mu}$M range found for compounds listed in [Table 7](#molecules-25-00938-t007){ref-type="table"}) could be its weaker solubility (cLogP of 5.7, greater than that of all compounds listed in [Table 7](#molecules-25-00938-t007){ref-type="table"}).

Another point concerned the interaction of F0514-4011 with amino acid residues within the protein-binding region. In [Table 8](#molecules-25-00938-t008){ref-type="table"}, we have listed the protein residues/ligand interactions found from [Table 7](#molecules-25-00938-t007){ref-type="table"} PDB complexes, as calculated by the PLIP program. These interactions were compared to the ones obtained for F0514-4011 from its best pose MD_3EFJ in the ensemble MET conformations. From this comparison, it appears that several of the most important amino acid residues found from the PDB protein/ligand analysis were also found for F0514-4011, at the exception of Met${}_{1160}$, common to all PDB structures of [Table 8](#molecules-25-00938-t008){ref-type="table"}, replaced possibly by Met${}_{1131}$ and Met${}_{1229}$ in our case. This situation is mostly due to the conformation of the large DFG loop acting as a highly flexible lid protecting the binding sites which was quite different in the MD_3EFJ conformation, found as the most suitable one to bind F0514-4011 when compared to the PDB ones (see [Figure 6](#molecules-25-00938-f006){ref-type="fig"} for an example with the 5DG5 and 4DEI structures). Therefore, our docking results concerning the best pose proposed by GOLD for F0514-4011 appear quite in agreement with most of data obtained from all the PDB concerning MET kinase domain complexed with inhibitors.

To further characterize the F0514-4011 inhibitor type, we have considered the general 3D shape of known kinase inhibitors as analyzed in several papers \[[@B7-molecules-25-00938],[@B65-molecules-25-00938],[@B66-molecules-25-00938],[@B67-molecules-25-00938]\]. Concerning MET, such compounds are generally classified as type-I or -II. Type-I ligands essentially bind at the ATP binding site and present a U-shaped conformation, with the protein in the DFG-in structure; while type II are found in an extended shape and correspond to the DFG-out protein form. We illustrate this in [Figure 7](#molecules-25-00938-f007){ref-type="fig"}, showing the conformations of two typical ligands, namely, type-I AMG337 (from PDB 5EYD) and the type-II altiratinin analog DP-4157 (from PDB 5DG5). From this picture, it appears that F0514-4011 presents both the U and linear shapes while also showing another region of interaction, including three of the protein residues already found in MET complexes---namely, Asp${}_{1222}$, Tyr${}_{1230}$, and Arg${}_{1208}$ (found only 2 times for 3C1X and 3YW8 among our 45 ensemble conformations). Asp${}_{1204}$ and Asn${}_{1209}$ residues, still not involved in MET complex PDB structures, complement this supplementary binding pocket. The thiophene moiety of F0514-4001 was placed central within this pocket by the thiophene-pyrazole group which also oriented the associated toluene ring to close the U-shape part. Therefore, one could postulate that F0514-4011 molecule describes a possibly novel type of inhibitor.

Nevertheless, considering the limitations of any docking program, the stability of F0514-4011's best docking pose could be questioned. In order to validate it, we have performed a molecular dynamics simulation using the same conditions as those used for the PDB complexes (cubic water box of 80 Å^3^). The results show that the GOLD docking pose is very stable and still conserved after 10 ns of MD ([Figure 8](#molecules-25-00938-f008){ref-type="fig"}). The protein/ligand interactions found for F0514-4011 after the MD simulation were similar to those discussed above, thus giving confidence to the robustness of the docking results. Our final question concerns the originality of F0514-4011 compared to the known MET ligands. The Tanimoto similarity index calculated between F0514-4011 and most of the published MET ligands shows that the molecule identified by our virtual screening campaign seems to be an innovative hit as all the Tanimoto values are low, ranging from 0.39 (with the pioneer inhibitor PHA-665752) to 0.12 (for norcantharidin) ([Table S2](#app1-molecules-25-00938){ref-type="app"}). We have completed this quite elementary similarity search by using the ChemDes web server \[[@B68-molecules-25-00938]\], which allows a large panel of similarity fingerprint types as well as fingerprints descriptors and similarity measures. Using this web server, we mined several databases collecting MET known inhibitors (such as the PDB or PubChem \[[@B69-molecules-25-00938]\]), already in clinical trials (such as MDDR \[[@B70-molecules-25-00938]\]), or described as putative inhibitors (such as in Life Chemical or sellekchem \[[@B71-molecules-25-00938]\] providers). The results obtained with this method confirmed the lack of similarity suggested with the Tanimoto distance. With the Sokal similarity method and DTRF fingerprint types, the similarities ranged from 0.46 to 0.19 (in the PDB list, a maximum of 0.40 was obtained for compound ID 75H found in PDB ID 5T3Q (data not shown)).This could be due to the thiophene moiety of F0514-4011, as we have found only two papers and one patent in the literature referring to thiophene-related MET inhibitors \[[@B72-molecules-25-00938],[@B73-molecules-25-00938],[@B74-molecules-25-00938]\] and only one reference to the role of thiophene-pyrazole moiety in kinase inhibition \[[@B75-molecules-25-00938]\].

4. Discussion {#sec4-molecules-25-00938}
=============

Molecular docking, molecular dynamics, and virtual screening approaches can now be efficiently used for the design of new inhibitors of the MET kinase domain \[[@B27-molecules-25-00938],[@B56-molecules-25-00938],[@B76-molecules-25-00938],[@B77-molecules-25-00938],[@B78-molecules-25-00938],[@B79-molecules-25-00938],[@B80-molecules-25-00938]\]. From all these approaches, new potent compounds were obtained and more highlights revealed about MET kinase domain conformational behavior. In this vein, our study merges both simulations and experiments and highlights a novel scaffold for MET inhibition.

Using an ensemble-docking approach associated to short molecular dynamics runs in order to take into account the flexibility of the used X-ray structures in the protein conformational ensemble, we were faced with the fundamental question of the relevance of this strategy for handling the difficult problem of predicting ligand-binding modes on a flexible target. This is especially true for MET kinase, the active site of which exhibits important structural variations, as observed in their available crystal structures \[[@B81-molecules-25-00938],[@B82-molecules-25-00938]\]. We believe that this work brings a positive answer to this question and can constitute a working line for other simulations in the future. Ensemble-docking is now widely used, and incorporating this approach to short molecular dynamics simulations looks promising. Still, a couple of simple questions have to be answered prior to initiating the docking calculation: how do we generate a relevant ensemble for a given receptor \[[@B51-molecules-25-00938]\], and how can we be sure that the possible energy differences obtained between conformations in the ensemble are properly accounted for?

Interestingly, F0514-4011 compound (also referenced in PubChem with ID 5237313) is not a newcomer in drug design as it has been already tested as a possible activator of E3 ligase (FBW7) and inhibitor of microphthalmia-associated transcription factor (MITF), but was found inactive in both assays. Our study suggests that it could be repositioned for MET inhibition, as evidenced by its biological activity against MET-driven cell scattering. Some drug properties such as solubility and lack of toxicity were already known. With regard to its molecular weight of 650Da, which could be considered as limiting its possible therapeutic action, it should be noted that other inhibitors currently on the market have similar characteristics such as tarloxatinib (679Da), foretinib (632Da), or golvatinib (633Da). Therefore, it should not be a major hurdle if lead optimization provides us with a promising drug in terms of activity and/or selectivity. This will be the topic of future investigations.

This virtual screening work presents F0414-4011 as a valuable compound that could be a seed for developing new and innovative leads against MET kinase. Its novelty and originality might be used to overcome the resistance problem found presently for several existing inhibitors.

Experiments presented in this paper were carried out using the Grid'5000 testbed, supported by a scientific interest group hosted by Inria and including CNRS, RENATER, and several Universities as well as other organizations (see <https://www.grid5000.fr>). We are much grateful to all members of our labs for helpful discussion and advice.
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![(**a**) Dendrogram showing the relationships between the 45 PDB conformers listed in [Table 2](#molecules-25-00938-t002){ref-type="table"} and [Table 3](#molecules-25-00938-t003){ref-type="table"} and used to sample MET structure plasticity. (**b**) Similarity heat-map showing the relationships between the 45 PDB conformers and used to sample MET structure plasticity. The color scale corresponds to the Dali Z-score values. (**c**) Correspondence analysis of the 45 ensemble PDB-related conformers. This plot positions data points with the most similar structural neighborhoods near each other according to a multidimensional scaling method.](molecules-25-00938-g001){#molecules-25-00938-f001}

![Position of the average center-point (as a green sphere) found from the 45 used conformers and used for the ensemble-dockings.](molecules-25-00938-g002){#molecules-25-00938-f002}

![Poses of the AM7 ligand in the X-ray 2RFN structure compared to the docking results. In black, the original pose of the ligand in its PDB protein conformation; in colors, the best docking poses obtained by GOLD on the 2RFN target using a definition of the binding site from a list of residues (orange), from the original ligand (green), and from a center-point (purple).](molecules-25-00938-g003){#molecules-25-00938-f003}

![(**a**) F0514-4011 impairs cell scattering in response to MET ligand HGF: MDCK epithelial cells were treated with 20 ng/mL HGF, with or without preincubation with F0514-4011 for 2 h. F0514-4011 IC${}_{50}$ is 7.2 $\mathsf{\mu}$M. (**b**) Dose-response curve for F0514-4011.](molecules-25-00938-g004){#molecules-25-00938-f004}

![F0514-4011: N-\[\[4-(4-Ethoxyphenyl)-5-\[2-\[3-(4-methylphenyl)-5-thiophen-2-yl-3,4-dihydropyrazol -2-yl\]-2-oxoethyl\]sulfanyl-1,2,4-triazol-3-yl\]methyl\]-2-phenylacetamide.](molecules-25-00938-g005){#molecules-25-00938-f005}

![Differences for the lid DFG loop between selected PDB structures and our MD-refined MD_3EFJ conformations. The proteins are depicted from their C${}^{\alpha}$ ribbon-like traces.](molecules-25-00938-g006){#molecules-25-00938-f006}

![Comparison of the conformations between F0514-4011, the U-shape inhibitor 5T1 (AMG337), and the linear-shape 5B4 (altiratinib), as observed in their respective binding sites.](molecules-25-00938-g007){#molecules-25-00938-f007}

![(**a**) Comparison between the initial docking pose (in orange) of F0514-4011 and the final one after the 10-ns MD simulation (in cyan). (**b**) Evolution of F0514-4011 root mean square deviation (RMSD) during 11 ns (1 ns equilibrium and 10 ns production) of MD simulation. Poses were aligned on the initial one and the curve was smoothed.](molecules-25-00938-g008){#molecules-25-00938-f008}

molecules-25-00938-t001_Table 1

###### 

List of the selected chemical libraries used in the present virtual screening campaign, providing a total of 76,251 compounds.

  Supplier                                                                                 Library Names
  ---------------------------------------------------------------------------------------- ---------------------------------------------
  French laboratories [chimiotheque-nationale.enscm.fr](chimiotheque-nationale.enscm.fr)   Selected subsets (kinase, essential, etc.)
  Collaboration [medchem.u-strasbg.fr](medchem.u-strasbg.fr)                               laboratory collection
  ChemBridge [www.chembridge.com/index.php](www.chembridge.com/index.php)                  kinase library diversity library
  Life Chemicals [www.lifechemicals.com](www.lifechemicals.com)                            kinase general library antiviral library
                                                                                           15K diversity library
  TimTec [www.timtec.net](www.timtec.net)                                                  NDL + NPL natural derivatives library
  Otava [otavachemicals.com](otavachemicals.com)                                           all kinase library
                                                                                           10K diversity library
                                                                                           natural productlike library
  TargetMol [www.targetmol.com](www.targetmol.com)                                         antivirus library natural compounds library

molecules-25-00938-t002_Table 2

###### 

List of the 26 PDB MET kinase domain structures selected in the previous work \[[@B22-molecules-25-00938]\] and reused in the present one. The kinase conformation associated to each structure is annotated according to the KinaMetrix web resource \[[@B56-molecules-25-00938]\]: DO means DFG-out, DI means DFG-in, CO means $\alpha$-cHelix-out, CI means $\alpha$-cHelix-in, and $\omega$CD indicates DFG intermediate.

  N^*o*^   PDB ID   Ligand PDB ID   Deposition Date   Annotation
  -------- -------- --------------- ----------------- ---------------------
  1        1R0P     KSA             2003              Inactive CODI
  2        2RFN     AM7             2007              ?
  3        2RFS     AM8             2007              Inactive CODI
  4        3C1X     CKK             2008              Inactive CIDO
  5        3CCN     LKG             2008              Inactive CODI
  6        3CD8     L5G             2008              Inactive CODI
  7        3CE3     1FN             2008              Inactive CODO
  8        3CTH     319             2008              Inactive CIDO
  9        3CTJ     320             2008              Inactive CIDO
  10       3F66     IHX             2008              Inactive CODI
  11       3F82     353             2008              Inactive CIDO
  12       3EFJ     MT3             2008              Inactive CODO
  13       3EFK     MT4             2008              Inactive CODI
  14       2WD1     ZZY             2009              Inactive CODI
  15       3DKC     ATP             2009              Inactive CODI
  16       3DKF     SX8             2009              Inactive CODI
  17       2WGJ     VGH             2009              Active CIDI
  18       3A4P     DFQ             2010              Inactive CODI
  19       3L8V     L8V             2010              Inactive CIDO
  20       3I5N     B2D             2010              Inactive CODI
  21       3LQ8     88Z             2010              Inactive CODO
  22       2WKM     PFY             2010              Inactive CODI
  23       3Q6W     Q6W             2011              Active CIDI
  24       3QTI     3QT             2011              Inactive CODI
  25       3RHK     M97             2011              Inactive $\omega$CD
  26       3ZXZ     KRW             2011              Inactive CODI

molecules-25-00938-t003_Table 3

###### 

List of the PDB MET kinase domain structures added to the ones coming from our previous work \[[@B22-molecules-25-00938]\]. The kinase conformation associated to each structure is annotated according to the KinaMetrix web resource \[[@B56-molecules-25-00938]\]: DO means DFG-out, DI means DFG-in, CO means $\alpha$-cHelix-out, CI means $\alpha$-cHelix-in, and $\omega$CD indicates DFG intermediate.

  N^*o*^   PDB ID   Ligand ID   Ligand IC$\mathbf{{}_{50}}$ (nM)   Date   Missing Sequence        \# Missing Residues   Annotation
  -------- -------- ----------- ---------------------------------- ------ ----------------------- --------------------- ---------------
  1        4DEI     0JL         0.6--2                             2012   1100--1103 1115--1117   7                     Inactive CODI
  2        4GG5     0J3         0.9                                2012   1146--1151              6                     Inactive CODI
  3        4EEV     L1X         4.7/42                             2012   1225--1243              19                    Inactive CIDO
  4        3VW8     DF6         2                                  2013   1237--1242 1286--1290   11                    ?
  5        4IWD     1JC         1                                  2013   1234--1235 1240--1243   6                     Active CIDI
  6        3ZCL     5TF         19                                 2013   1100--1102              3                     Inactive CODI
  7        3ZC5     W9Z         6                                  2013   1099--1102              4                     Inactive CODI
  8        3ZBX     6XE         5                                  2013   1089--1102              14                    Inactive CODI
  9        4KNB     1RU         47/410                             2013   1099--1103 1113--1115   8                     Inactive CODI
  10       4MXC     DWF         6.7                                2014   1238--1242              5                     Inactive CODO
  11       4XYF     44X         1/5                                2015   1099--1103              5                     
  12       4R1V     3E8         400                                2015   1150--1151              2                     Inactive CODI
  13       4XMO     46G         2                                  2015   1098--1103              6                     Inactive CODI
  14       5DG5     5B4         ?                                  2015   \-                      \-                    Inactive CODO
  15       5EYD     5T1         1                                  2016   1098--1103 1151--1152   8                     Inactive CODI
  16       5EOB     5QQ         0.24                               2016   1238--1240              3                     Inactive CODI
  17       5EYC     5SZ         3                                  2016   1099--1103              5                     Inactive CODI
  18       5UAF     84P         ?                                  2017   1098--1105 1145--1152   16                    Active CIDI
  19       5HTI     66L         ?                                  2017   1238--1242              5                     Inactive CODO

molecules-25-00938-t004_Table 4

###### 

List of the secondary structure elements used for aligning all the conformers.

  Domain       Secondary Structure Name   Residues
  ------------ -------------------------- --------------
  N-terminal   $\beta$1                   1076 to 1081
               $\beta$2                   1092 to 1098
               $\beta$2                   1104 to 1110
               $\beta$2                   1144 to 1146
               $\beta$2                   1154 to 1158
  C-terminal   $\alpha$E                  1178 to 1198
               $\alpha$F                  1263 to 1278
               $\alpha$H                  1310 to 1320
               $\alpha$I                  1330 to 1343

molecules-25-00938-t005_Table 5

###### 

Comparison of the docking results using the 3 binding site definitions.

  Definition of the Binding Site   Target PDB Name   Ligand PDB Name   Rank Number   Score Value
  -------------------------------- ----------------- ----------------- ------------- -------------
  Center + radius 20 Å             3DKC              ATP               1             105.5
                                   2RFN              AM7               1             100.8
  Residues list                    3DKC              ATP               1             102.8
                                   2RFN              AM7               1             98.0
  From its PDB ligand              3DKC              ATP               1             107.1
                                   2RFN              AM7               1             106.6

molecules-25-00938-t006_Table 6

###### 

Ligands selected from the Life Chemical (LC) antiviral library and experimentally tested. "-": the compound (assessed at a concentration up to 100 $\mathsf{\mu}$M) did not affect MDCK cell scattering in response to HGF/SF. "+": the compound impaired MDCK cell scattering in response to HGF/SF with an IC${}_{50}$ \> 10 $\mathsf{\mu}$M. "+++": the compound impaired MDCK cell scattering in response to HGF/SF with an IC${}_{50}$ \< 10 $\mathsf{\mu}$M.

  Mol ID   Life Chemicals Name   GOLD Score   Best Protein Conformer   Biological Activity
  -------- --------------------- ------------ ------------------------ ---------------------
  1        F0725-0356            120.7        MD_3EFK                  \-
  2        F0772-0607            111.8        MD_3EFK                  \-
  3        F0816-0342            111.2        MD_3F82                  \-
  4        F0737-0405            110.6        MD_3EFJ                  \-
  5        F0737-0393            110.1        MD_3EFK                  \-
  6        F0301-0263            105.5        MD_3EFK                  \-
  7        F0721-0868            105.1        MD_3EFK                  \-
  8        F0715-0299            105.0        MD_3EFK                  \-
  9        F0539-1482            104.0        MD_3EFJ                  \+
  10       F0385-0029            103.8        MD_3EFK                  \-
  11       F0385-0334            103.4        MD_3EFJ                  \-
  12       F0514-4011            103.3        MD_3EFJ                  +++
  13       F0174-0048            102.4        MD_3EFK                  \-
  14       F1620-0074            102.1        MD_3EFJ                  \-
  15       F0011-0324            102.0        MD_3EFK                  \-
  16       F0721-0906            102.0        MD_3EFJ                  \-
  17       F0012-0227            101.9        MD_3EFJ                  \-
  18       F0721-0911            101.9        MD_3EFJ                  \-
  19       F0715-0300            101.8        MD_2RFN                  \-
  20       F2252-0240            101.1        MD_3EFK                  \-
  21       F0772-2099            100.9        MD_3EFJ                  \-
  22       F0473-0261            100.9        MD_3CE3                  \-
  23       F0721-0900            100.5        MD_3EFK                  \-
  24       F0772-2147            100.5        MD_3EFJ                  \-
  25       F0526-0094            100.3        MD_3EFJ                  \-

molecules-25-00938-t007_Table 7

###### 

Data used for some known marketed inhibitors with nano-molar range IC${}_{50}$ found in the PDB.

  PDB ID   Ligand ID   Name          IC50     Solubility cLogP   Docking Score
  -------- ----------- ------------- -------- ------------------ ---------------
  2RFS     AM8         SU11274       10 nM    2.9                86
  2WGJ     VGH         Criotinib     11 nM    3.5                82
  2WKM     PFY         PHA-665752    9 nM     4.4                88
  3DKF     SX8         SGX-523       4 nM     1.4                84
  3RHK     M97         Tivantinib    4 nM     3.1                83
  3LQ8     88Z         Fortinib      0.4 nM   4.3                99
  3Q6W     Q6W         MK-2461       0.4 nM   3.3                93
  3QTI     3QT         NVP-BVU972    14 nM    1.6                84
  3ZXZ     KRW         PF-04217903   5 nM     0.2                87
  4EEV     L1X         Merestinib    5 nM     3.4                111
  5EYD     5T1         AMG337        1 nM     0.3                83

molecules-25-00938-t008_Table 8

###### 

List of the protein residues interacting with a nM. inhibitor from the PDB complexes of [Table 7](#molecules-25-00938-t007){ref-type="table"} ranked by their number of occurrence. In bold, the residues also found in the interactions with F0514-4011 with the MD-3EFJ MET conformation. According to the PLIP results, a residue was marked "+" when at least one protein-ligand interaction was found, whatever its quality (hydrophobic, H-bond, $\pi$-stacking, ionic, etc.) and marked by "-" when no protein-ligand interaction was found.

                       PDB IDs                                                
  -------------------- --------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  MET${}_{1160}$       \+        \+   \+   \+   \+   \+   \+   \+   \+   \+   \+
  **LEU${}_{1157}$**   \+        \+   \+   \-   \+   \+   \+   \+   \+   \+   \+
  **ASP${}_{1222}$**   \+        \-   \+   \+   \+   \-   \+   \-   \-   \+   \+
  ALA${}_{1108}$       \+        \-   \+   \+   \-   \-   \+   \+   \-   \+   \+
  TYR${}_{1230}$       \-        \+   \+   \+   \+   \-   \+   \-   \+   \+   \-
  **VAL${}_{1092}$**   \-        \+   \-   \+   \-   \+   \+   \+   \-   \+   \-
  **ILE${}_{1084}$**   \+        \+   \+   \+        \+   \+   \+   \-   \+   \+
  TYR${}_{1159}$       \-        \-   \-   \-   \-   \-   \-   \+   \+   \-   \+
  PRO${}_{1158}$       \-        \+   \-   \-   \+   \+   \-   \-   \+   \-   \-
  **LEU${}_{1140}$**   \-        \-   \-   \-   \+   \-   \-   \+   \+   \-   \+
  **ALA${}_{1221}$**   \-        \-   \-   \-   \-   \-   \+   \+   \-   \+   \-
  **PHE${}_{1223}$**   \+        \-   \-   \-   \-   \+   \-   \-   \-   \-   \+
  ASP${}_{1164}$       \-        \-   \-   \-   \-   \-   \-   \-   \+   \+   \-
  **LYS${}_{1110}$**   \+        \-   \-   \-   \-   \+   \-   \-   \-   \-   \-
  ASN${}_{1209}$       \-        \-   \-   \-   \-   \-   \-   \-   \+   \-   \-
  GLU${}_{1127}$       \-        \-   \-   \-   \-   \-   \-   \-   \-   \-   \+
  PHE${}_{1134}$       \+        \-   \-   \-   \-   \-   \-   \-   \-   \-   \+
  VAL${}_{1139}$       \+        \-   \-   \-   \-   \-   \-   \-   \-   \-   \+
  PHE${}_{1200}$       \+        \-   \-   \-   \-   \-   \-   \-   \-   \-   \+
  ARG${}_{1086}$       \-        \-   \-   \-   \-   \-   \-   \+   \-   \-   \-
  ARG${}_{1208}$       \-        \-   \-   \-   \-   \-   \-   \+   \-   \-   \-
  THR${}_{1343}$       \-        \-   \-   \-   \-   \-   \+   \-   \-   \-   \-
  GLU${}_{1347}$       \-        \-   \-   \-   \-   \-   \+   \-   \-   \-   \-
  **PHE${}_{1089}$**   \-        \-   \-   \-   \-   \+   \-   \-   \-   \-   \-
  ASP${}_{1231}$       \-        \-   \-   \+   \-   \-   \-   \-   \-   \-   \-
  ARG${}_{1166}$       \-        \-   \-   \+   \-   \-   \-   \-   \-   \-   \-
  ASN${}_{1167}$       \-        \-   \-   \+   \-   \-   \-   \-   \-   \-   \-
  ILE${}_{1130}$       \+        \-   \-   \-   \-   \-   \-   \-   \-   \-   \-
  ASN${}_{1171}$       \-        \-   \-   \-   \-   \-   \-   \-   \-   \-   \-

[^1]: These authors contributed equally to this work.
